These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9420050)

  • 1. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
    Koga T; Abe T; Inoue H; Takenouchi T; Kitayama A; Yoshida T; Masuda N; Sugihara C; Kakuta M; Nakagawa M; Shibayama T; Matsushita Y; Hirota T; Ohya S; Utsui Y; Fukuoka T; Kuwahara S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3239-50. PubMed ID: 16048932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
    Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
    Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.
    Di Modugno E; Erbetti I; Ferrari L; Galassi G; Hammond SM; Xerri L
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2362-8. PubMed ID: 7840571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
    Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
    Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
    Tsuji M; Ishii Y; Ohno A; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Jan; 42(1):94-9. PubMed ID: 9449267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.
    Yamaguchi K; Domon H; Miyazaki S; Tateda K; Ohno A; Ishii K; Matsumoto T; Furuya N
    Antimicrob Agents Chemother; 1998 Mar; 42(3):555-63. PubMed ID: 9517932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.